SYROS PHARMACEUTICALS INC's ticker is SYRS and the CUSIP is 87184Q107. A total of 91 filers reported holding SYROS PHARMACEUTICALS INC in Q4 2021. The put-call ratio across all filers is 6.64 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2021 | $5,990,000 | -27.1% | 1,837,500 | 0.0% | 0.08% | -14.4% |
| Q3 2021 | $8,214,000 | -18.0% | 1,837,500 | 0.0% | 0.09% | -10.9% |
| Q2 2021 | $10,014,000 | -27.1% | 1,837,500 | 0.0% | 0.10% | -21.7% |
| Q1 2021 | $13,745,000 | -18.9% | 1,837,500 | +17.6% | 0.13% | -12.8% |
| Q4 2020 | $16,953,000 | – | 1,562,500 | – | 0.15% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ally Bridge Group (NY) LLC | 3,539,895 | $11,540,000 | 4.03% |
| Bain Capital Life Sciences Investors, LLC | 6,264,420 | $20,422,000 | 1.62% |
| Samsara BioCapital, LLC | 2,189,199 | $6,243,000 | 1.21% |
| Omega Fund Management, LLC | 2,512,705 | $8,191,000 | 1.16% |
| Altium Capital Management LP | 1,160,000 | $3,782,000 | 1.04% |
| Sio Capital Management, LLC | 900,677 | $2,936,000 | 0.88% |
| Artal Group S.A. | 3,000,000 | $9,780,000 | 0.26% |
| Flagship Pioneering Inc. | 2,938,494 | $9,579,000 | 0.15% |
| GSA CAPITAL PARTNERS LLP | 242,132 | $789,000 | 0.10% |
| Orbimed Advisors | 1,837,500 | $5,990,000 | 0.08% |